Relapsed and Refractory Multiple Myeloma
13
1
2
4
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
30.8%
4 terminated out of 13 trials
50.0%
-36.5% vs benchmark
8%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
IPD in RRMM Characterized with Genomic Abnormalities of Adverse Prognostic
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
Study of BCMA CAR-T in Multiple Myeloma
Efficacy Study of CYT997 in Multiple Myeloma
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies